Cadila Healthcare is currently trading at Rs. 257.80, up by 3.40 points or 1.34% from its previous closing of Rs. 254.40 on the BSE.
The scrip opened at Rs. 253.85 and has touched a high and low of Rs. 259.10 and Rs. 251.85 respectively. So far 72694 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 370.00 on 03-Dec-2018 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 265.50 and Rs. 251.50 respectively. The current market cap of the company is Rs. 26417.68 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.13% and 8.00% respectively.
Cadila Healthcare has received an approval from the board of directors for the amalgamation of Zydus Technologies (ZTL), Alidac Pharmaceuticals (APL), Liva Pharmaceuticals (LPL) and Dialforhealth India (DHIL) with the company.
The amalgamation is being done for consolidation of pharmaceutical business and merger simplification of corporate structure to avoid duplication of effort and to reduce the overheads and costs of managing separate entities.
Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.